Clinical trials show approximately 2040% of total weight lost with GLP-1 medications includes lean mass, comparable to dietary restriction and bariatric surgery
SAEs according to baseline BMI category
However, EHR data showed smaller changes in BMI compared with baseline, with a median BMI % of 5.79%, which is significantly less than that reported in the self-report surveys (11.8%, P = 2.4 10 55 )
Start your medically guided weight loss journey today
Efficacy and safety of once-weekly semaglutide 20 mg versus 10 mg inpatients with type 2diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial
Boxing out the competition CVS's July 1st formulary switch from Zepbound to Wegovy delivered what UBS called a 'step change' in total prescription volume, helping Wegovy maintain 40%+ market share for over five consecutive weeks